Trust Co Of Toledo Na Oh buys $4,336,927 stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Trust Co Of Toledo Na Oh scooped up 1,908 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 25, 2016. The investment management firm now holds a total of 74,009 shares of Merck & Co. which is valued at $4,336,927.Merck & Co. makes up approximately 1.23% of Trust Co Of Toledo Na Oh’s portfolio.

Other Hedge Funds, Including , Msi Financial Services Inc boosted its stake in MRK in the latest quarter, The investment management firm added 10,088 additional shares and now holds a total of 107,217 shares of Merck & Co. which is valued at $6,282,916. Merck & Co. makes up approx 0.22% of Msi Financial Services Inc’s portfolio.Willingdon Wealth Management boosted its stake in MRK in the latest quarter, The investment management firm added 2,296 additional shares and now holds a total of 36,786 shares of Merck & Co. which is valued at $2,163,753. Merck & Co. makes up approx 1.07% of Willingdon Wealth Management’s portfolio.James Investment Research Inc boosted its stake in MRK in the latest quarter, The investment management firm added 62,435 additional shares and now holds a total of 747,627 shares of Merck & Co. which is valued at $44,124,946. Merck & Co. makes up approx 1.09% of James Investment Research Inc’s portfolio.Laurel Wealth Advisors reduced its stake in MRK by selling 637 shares or 3.42% in the most recent quarter. The Hedge Fund company now holds 17,981 shares of MRK which is valued at $1,067,172. Merck & Co. makes up approx 0.52% of Laurel Wealth Advisors’s portfolio.

Merck & Co. opened for trading at $59.01 and hit $59.2 on the upside on Friday, eventually ending the session at $58.66, with a gain of 0.39% or 0.23 points. The heightened volatility saw the trading volume jump to 84,91,237 shares. Company has a market cap of $162,372 M.

On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.